Treatment of Peripheral Artery Disease
All patients with symptomatic PAD should receive comprehensive medical therapy consisting of single antiplatelet therapy (preferably clopidogrel 75 mg daily), high-intensity statin therapy, blood pressure control, smoking cessation, and supervised exercise therapy—this combination reduces both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). 1, 2
Medical Therapy Framework
Antiplatelet/Antithrombotic Therapy
First-line antiplatelet therapy:
- Clopidogrel 75 mg daily is the preferred single antiplatelet agent 1
- Aspirin 75-325 mg daily is an acceptable alternative 1
- For asymptomatic PAD, single antiplatelet therapy is reasonable to reduce MACE risk 1
Enhanced antithrombotic regimen for high-risk patients:
- Rivaroxaban 2.5 mg twice daily PLUS aspirin 100 mg daily should be considered for patients with high ischemic risk and non-high bleeding risk 1, 2
- This combination significantly reduces both MACE and MALE compared to aspirin alone 1
- Critical caveat: This comes with increased gastrointestinal bleeding risk—carefully assess bleeding risk before initiating 3
Lipid Management
- High-intensity statin therapy is mandatory for all PAD patients 1, 2, 4
- Consider adding PCSK9 inhibitor in very high-risk patients 2
- If triglycerides >1.5 mmol/L despite statin therapy, icosapent ethyl 2 g twice daily may be considered 2
- Fibrates are NOT recommended for cholesterol lowering 2
Additional Medical Therapies
- Blood pressure control: ACE inhibitors or ARBs are recommended 5, 6
- Diabetes management: Prioritize GLP-1 receptor agonists and SGLT-2 inhibitors 4
- Smoking cessation is non-negotiable—this is one of the most modifiable risk factors 1, 7, 5
Supervised Exercise Therapy (SET)
SET is a Class I recommendation and should be prescribed to all symptomatic PAD patients 2:
- Minimum parameters: 3 sessions per week, 30 minutes per session, for at least 12 weeks 2
- Intensity: High-intensity walking (77-95% max heart rate or 14-17 on Borg scale) 2
- Walking to moderate-severe claudication pain improves outcomes 2
- When SET unavailable, structured home-based exercise therapy (HBET) with monitoring should be considered 2
- SET is also recommended as adjuvant therapy after endovascular revascularization 2
Post-Revascularization Antithrombotic Management
After endovascular or surgical revascularization:
- Rivaroxaban 2.5 mg twice daily PLUS aspirin is the preferred regimen to reduce MACE and MALE 1, 2
- Alternatively, dual antiplatelet therapy (P2Y12 inhibitor + aspirin) is reasonable for 1-6 months after endovascular procedures 1
- For prosthetic surgical grafts, dual antiplatelet therapy should be considered 1
Revascularization Decision Algorithm
Revascularization should be considered ONLY after:
- 3 months of optimal medical therapy (OMT) and exercise therapy 2
- Assessment shows impaired PAD-related quality of life despite OMT 2
- Patient has lifestyle-limiting claudication 5
Key restrictions:
- Revascularization is NOT recommended solely to prevent progression to chronic limb-threatening ischemia (CLTI) 2
- Revascularization is NOT recommended for asymptomatic PAD 2
- For femoropopliteal lesions, drug-eluting treatment should be first-choice endovascular strategy 2
Evidence Strength and Adherence Impact
Adherence to all four guideline-recommended therapies (antiplatelet, statin, ACE inhibitor, smoking cessation) reduces:
Yet only 32% of PAD patients receive all four recommended therapies 6—this represents a massive treatment gap.
Common Pitfalls to Avoid
- Don't use dual antiplatelet therapy routinely in symptomatic PAD without recent revascularization—benefit is uncertain 1
- Don't add vorapaxar to antiplatelet therapy—benefit is uncertain 1
- Don't skip the 3-month trial of OMT + exercise before considering revascularization unless patient has CLTI or acute limb ischemia 2
- Don't forget that polypharmacy affects 39% of older adults—use shared decision-making to tailor therapy 1